,0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681,682,683,684,685,686,687,688,689,690,691,692,693,694,695,696,697,698,699,700,701,702,703,704,705,706,707,708,709,710,711,712,713,714,715,716,717,718,719,720,721,722,723,724,725,726,727,728,729,730,731,732,733,734,735,736,737,738,739,740,741,742,743,744,745,746,747,748,749,750,751,752,753,754,755,756,757,758,759,760,761,762,763,764,765,766,767,768,769,770,771,772,773,774,775,776,777,778,779,780,781,782,783,784,785,786,787,788,789,790,791,792,793,794,795,796,797,798,799,800,801,802,803,804,805,806,807,808,809,810,811,812,813,814,815,816,817,818,819,820,821,822,823,824,825,826,827,828,829,830,831,832,833,834,835,836,837,838,839,840,841,842,843,844,845,846,847,848,849,850,851,852,853,854,855,856,857,858,859,860,861,862,863,864,865,866,867,868,869,870,871,872,873,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,891,892,893,894,895,896,897,898,899,900,901,902,903,904,905,906,907,908,909,910,911,912,913,914,915,916,917,918,919,920,921,922,923,924,925,926,927,928,929,930,931,932,933,934,935,936,937,938,939,940,941,942,943,944,945,946,947,948,949,950,951,952,953,954,955,956,957,958,959,960,961,962,963,964,965,966,967,968,969,970,971,972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000,1001,1002,1003,1004,1005,1006,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018,1019,1020,1021,1022,1023,1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,1037,1038,1039,1040,1041,1042,1043,1044,1045,1046,1047,1048,1049,1050,1051,1052,1053,1054,1055,1056,1057,1058,1059,1060,1061,1062,1063,1064,1065,1066,1067,1068,1069,1070,1071,1072,1073,1074,1075,1076,1077,1078,1079,1080,1081,1082,1083,1084,1085,1086,1087,1088,1089,1090,1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119,1120,1121,1122,1123,1124,1125,1126,1127,1128,1129,1130,1131,1132,1133,1134,1135,1136,1137,1138,1139,1140,1141,1142,1143,1144,1145,1146,1147,1148,1149,1150,1151,1152,1153,1154,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175,1176,1177,1178,1179,1180,1181,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192,1193,1194,1195,1196,1197,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1208,1209,1210,1211,1212,1213,1214,1215,1216,1217,1218,1219,1220,1221,1222,1223,1224,1225,1226,1227,1228,1229,1230,1231,1232,1233,1234,1235,1236,1237,1238,1239,1240,1241,1242,1243,1244,1245,1246,1247,1248,1249,1250,1251,1252,1253,1254,1255,1256,1257,1258,1259,1260,1261,1262,1263,1264,1265,1266,1267,1268,1269,1270,1271,1272,1273,1274,1275,1276,1277,1278,1279,1280,1281,1282,1283,1284,1285,1286,1287,1288,1289,1290,1291,1292,1293,1294,1295,1296,1297,1298,1299,1300,1301,1302,1303,1304,1305,1306,1307,1308,1309,1310,1311,1312,1313,1314,1315,1316,1317,1318,1319,1320,1321,1322,1323,1324,1325,1326,1327,1328,1329,1330,1331,1332,1333,1334,1335,1336,1337,1338,1339,1340,1341,1342,1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1360,1361,1362,1363,1364,1365,1366,1367,1368,1369,1370,1371,1372,1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,1406,1407,1408,1409,1410,1411,1412,1413,1414,1415,1416,1417,1418,1419,1420,1421,1422,1423,1424,1425,1426,1427,1428,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439,1440,1441,1442,1443,1444,1445,1446,1447,1448,1449,1450,1451,1452,1453,1454,1455,1456,1457,1458,1459,1460,1461,1462,1463,1464,1465,1466,1467,1468,1469,1470,1471,1472,1473,1474,1475,1476,1477,1478,1479,1480,1481,1482,1483,1484,1485,1486,1487,1488,1489,1490,1491,1492,1493,1494,1495,1496,1497,1498,1499,1500,1501,1502,1503,1504,1505,1506,1507,1508,1509,1510,1511,1512,1513,1514,1515,1516,1517,1518,1519,1520,1521,1522,1523,1524,1525,1526,1527,1528,1529,1530,1531,1532,1533,1534,1535,1536,1537,1538,1539,1540,1541,1542,1543,1544,1545,1546,1547,1548,1549,1550,1551,1552,1553,1554,1555,1556,1557,1558,1559,1560,1561,1562,1563,1564,1565,1566,1567,1568,1569,1570,1571,1572,1573,1574,1575,1576,1577,1578,1579,1580,1581,1582,1583,1584,1585,1586,1587,1588,1589,1590,1591,1592,1593,1594,1595,1596,1597,1598,1599,1600,1601,1602,1603,1604,1605,1606,1607,1608,1609,1610,1611,1612,1613,1614,1615,1616,1617,1618,1619,1620,1621,1622,1623,1624,1625,1626,1627,1628,1629,1630,1631,1632,1633,1634,1635,1636,1637,1638,1639,1640,1641,1642,1643,1644,1645,1646,1647,1648,1649,1650,1651,1652,1653,1654,1655,1656,1657,1658,1659,1660,1661,1662,1663,1664,1665,1666,1667,1668,1669,1670,1671,1672,1673,1674,1675,1676,1677,1678,1679,1680,1681,1682,1683,1684,1685,1686,1687,1688,1689,1690,1691,1692,1693,1694,1695,1696,1697,1698,1699,1700,1701,1702,1703,1704,1705,1706,1707,1708,1709,1710,1711,1712,1713,1714,1715,1716,1717,1718,1719,1720,1721,1722,1723,1724,1725,1726,1727,1728,1729,1730,1731,1732,1733,1734,1735,1736,1737,1738,1739,1740,1741,1742,1743,1744,1745,1746,1747,1748,1749,1750,1751,1752,1753,1754,1755,1756,1757,1758,1759,1760,1761,1762,1763,1764,1765,1766,1767,1768,1769,1770,1771,1772,1773,1774,1775,1776,1777,1778,1779,1780,1781,1782,1783,1784,1785,1786,1787,1788,1789,1790,1791,1792,1793,1794,1795,1796,1797,1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1809,1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,1838,1839,1840,1841,1842,1843,1844,1845,1846,1847,1848,1849,1850,1851,1852,1853,1854,1855,1856,1857,1858,1859,1860,1861,1862,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872,1873,1874,1875,1876,1877,1878,1879,1880,1881,1882,1883,1884,1885,1886,1887,1888,1889,1890,1891,1892,1893,1894,1895,1896,1897,1898,1899,1900,1901,1902,1903,1904,1905,1906,1907,1908,1909,1910,1911,1912,1913,1914,1915,1916,1917,1918,1919,1920,1921,1922,1923,1924,1925,1926,1927,1928,1929,1930,1931,1932,1933,1934,1935,1936,1937,1938,1939,1940,1941,1942,1943,1944,1945,1946,1947,1948,1949,1950,1951,1952,1953,1954,1955,1956,1957,1958,1959,1960,1961,1962,1963,1964,1965,1966,1967,1968,1969,1970,1971,1972,1973,1974,1975,1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987,1988,1989,1990,1991,1992,1993,1994,1995,1996,1997,1998,1999,2000,2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015,2016,2017,2018,2019,2020,2021,2022,2023,2024,2025,2026,2027,2028,2029,2030,2031,2032,2033,2034,2035,2036,2037,2038,2039,2040,2041,2042,2043,2044,2045,2046,2047,2048,2049,2050,2051,2052,2053,2054,2055,2056,2057,2058,2059,2060,2061,2062,2063,2064,2065,2066,2067,2068,2069,2070,2071,2072,2073,2074,2075,2076,2077,2078,2079,2080,2081,2082,2083,2084,2085,2086,2087,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2112,2113,2114,2115,2116,2117,2118,2119,2120,2121,2122,2123,2124,2125,2126,2127,2128,2129,2130,2131,2132,2133,2134,2135,2136,2137,2138,2139,2140,2141,2142,2143,2144,2145,2146,2147,2148,2149,2150,2151,2152,2153,2154,2155,2156,2157,2158,2159,2160,2161,2162,2163,2164,2165,2166,2167,2168,2169,2170,2171,2172,2173,2174,2175,2176,2177,2178,2179,2180,2181,2182,2183,2184,2185,2186,2187,2188,2189,2190,2191,2192,2193,2194,2195,2196,2197,2198,2199,2200,2201,2202,2203,2204,2205,2206,2207,2208,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230,2231,2232,2233,2234,2235,2236,2237,2238,2239,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262,2263,2264,2265,2266,2267,2268,2269,2270,2271,2272,2273,2274,2275,2276,2277,2278,2279,2280,2281,2282,2283,2284,2285,2286,2287,2288,2289,2290,2291,2292,2293,2294,2295,2296,2297,2298,2299,2300,2301,2302,2303,2304,2305,2306,2307,2308,2309,2310,2311,2312,2313,2314,2315,2316,2317,2318,2319,2320,2321,2322,2323,2324,2325,2326,2327,2328,2329,2330,2331,2332,2333,2334,2335,2336,2337,2338,2339,2340,2341,2342,2343,2344,2345,2346,2347,2348,2349,2350,2351,2352,2353,2354,2355,2356,2357,2358,2359,2360,2361,2362,2363,2364,2365,2366,2367,2368,2369,2370,2371,2372,2373,2374,2375,2376,2377,2378,2379,2380,2381,2382,2383,2384,2385,2386,2387,2388,2389,2390,2391,2392,2393,2394,2395,2396,2397,2398,2399,2400,2401,2402,2403,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2415,2416,2417,2418,2419,2420,2421,2422,2423,2424,2425,2426,2427,2428,2429,2430,2431,2432,2433,2434,2435,2436,2437,2438,2439,2440,2441,2442,2443,2444,2445,2446,2447,2448,2449,2450,2451,2452,2453,2454,2455,2456,2457,2458,2459,2460,2461,2462,2463,2464,2465,2466,2467,2468,2469,2470,2471,2472,2473,2474,2475,2476,2477,2478,2479,2480,2481,2482,2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494,2495,2496,2497,2498,2499,2500,2501,2502,2503,2504,2505,2506,2507,2508,2509,2510,2511,2512,2513,2514,2515,2516,2517,2518,2519,2520,2521,2522,2523,2524,2525,2526,2527,2528,2529,2530,2531,2532,2533,2534,2535,2536,2537,2538,2539,2540,2541,2542,2543,2544,2545,2546,2547,2548,2549,2550,2551,2552,2553,2554,2555,2556,2557,2558,2559,2560,2561,2562,2563,2564,2565,2566,2567,2568,2569,2570,2571,2572,2573,2574,2575,2576,2577,2578,2579,2580,2581,2582,2583,2584,2585,2586,2587,2588,2589,2590,2591,2592,2593,2594,2595,2596,2597,2598,2599,2600,2601,2602,2603,2604,2605,2606,2607,2608,2609,2610,2611,2612,2613,2614,2615,2616,2617,2618,2619,2620,2621,2622,2623,2624,2625,2626,2627,2628,2629,2630,2631,2632,2633,2634,2635,2636,2637,2638,2639,2640,2641,2642,2643,2644,2645,2646,2647,2648,2649,2650,2651,2652,2653,2654,2655,2656,2657,2658,2659,2660,2661,2662,2663,2664,2665,2666,2667,2668,2669,2670,2671,2672,2673,2674,2675,2676,2677,2678,2679,2680,2681,2682,2683,2684,2685,2686,2687,2688,2689,2690,2691,2692,2693,2694,2695,2696,2697,2698,2699,2700,2701,2702,2703,2704,2705,2706,2707,2708,2709,2710,2711,2712,2713,2714,2715,2716,2717,2718,2719,2720,2721,2722,2723,2724,2725,2726,2727,2728,2729,2730,2731,2732,2733,2734,2735,2736,2737,2738,2739,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763,2764,2765,2766,2767,2768,2769,2770,2771,2772,2773,2774,2775,2776,2777,2778,2779,2780,2781,2782,2783,2784,2785,2786,2787,2788,2789,2790,2791,2792,2793,2794,2795,2796,2797,2798,2799,2800,2801,2802,2803,2804,2805,2806,2807,2808,2809,2810,2811,2812,2813,2814,2815,2816,2817,2818,2819,2820,2821,2822,2823,2824,2825,2826,2827,2828,2829,2830,2831,2832,2833,2834,2835,2836,2837,2838,2839,2840,2841,2842,2843,2844,2845,2846,2847,2848,2849,2850,2851,2852,2853,2854,2855,2856,2857,2858,2859,2860,2861,2862,2863,2864,2865,2866,2867,2868,2869,2870,2871,2872,2873,2874,2875,2876,2877,2878,2879,2880,2881,2882,2883,2884,2885,2886,2887,2888,2889,2890,2891,2892,2893,2894,2895,2896,2897,2898,2899,2900,2901,2902,2903,2904,2905,2906,2907,2908,2909,2910,2911,2912,2913,2914,2915,2916,2917,2918,2919,2920,2921,2922,2923,2924,2925,2926,2927,2928,2929,2930,2931,2932,2933,2934,2935,2936,2937,2938,2939,2940,2941,2942,2943,2944,2945,2946,2947,2948,2949,2950,2951,2952,2953,2954,2955,2956,2957,2958,2959,2960,2961,2962,2963,2964,2965,2966,2967,2968,2969,2970,2971,2972,2973,2974,2975,2976,2977,2978,2979,2980,2981,2982,2983,2984,2985,2986,2987,2988,2989,2990,2991,2992,2993,2994,2995,2996,2997,2998,2999,3000,3001,3002,3003,3004,3005,3006,3007,3008,3009,3010,3011,3012,3013,3014,3015,3016,3017,3018,3019,3020,3021,3022,3023,3024,3025,3026,3027,3028,3029,3030,3031,3032,3033,3034,3035,3036,3037,3038,3039,3040,3041,3042,3043,3044,3045,3046,3047,3048,3049,3050,3051,3052,3053,3054,3055,3056,3057,3058,3059,3060,3061,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3081,3082,3083,3084,3085,3086,3087,3088,3089,3090,3091,3092,3093,3094,3095,3096,3097,3098,3099,3100,3101,3102,3103,3104,3105,3106,3107,3108,3109,3110,3111,3112,3113,3114,3115,3116,3117,3118,3119,3120,3121,3122,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133,3134,3135,3136,3137,3138,3139,3140,3141,3142,3143,3144,3145,3146,3147,3148,3149,3150,3151
СЛОВО,Abstract:,Infections,in,childhood,play,an,essential,role,the,pathogenesis,of,cognitive,and,psycho-emotional,disorders.,One,possible,mechanisms,these,impairments,is,changes,functional,properties,NMDA,AMPA,glutamate,receptors,brain.,We,suggest,that,bacterial,infections,during,early,life,"period,",which,critical,for,excitatory,synapse,"maturation,",can,affect,subunit,composition,receptors.,In,present,"study,",we,investigated,effect,repetitive,lipopolysaccharide,(LPS),intraperitoneal,(i.p.),administration,(25 μg/kg/day,on,"P14,","16,","18),",mimicking,infectious,"disease,",expression,subunits,young,rats.,revealed,a,substantial,decrease,GluN2B,hippocampus,at,P23,using,Western,blot,analysis,real-time,polymerase,chain,reaction,assay.,Moderate,were,also,found,"GluN1,","GluN2A,",GluA1,mRNA,expression.,The,LPS-treated,rats,exhibited,decreased,exploratory,locomotor,activity,open,field,test,impairment,spatial,learning,Morris,water,maze.,Behavioral,accompanied,by,significant,reduction,long-term,hippocampal,synaptic,potentiation.,Our,data,indicate,LPS-treatment,period,maturation,alters,ionotropic,receptor,gene,"expression,",disturbs,"plasticity,","behavior.
",Prolonged,exposure,to,manganese,(Mn),may,lead,toxic,effects,central,nervous,system,(CNS).,underlying,neuronal,death,from,Mn,are,not,well,understood,but,undoubtedly,involve,inflammatory,processes.,aim,this,study,was,explore,long-lasting,intranasal,focusing,processes,catecholamine,"(dopamine,",norepinephrine),levels,striatum,hippocampus.,It,instillation,MnCl2,solution,once,day,90,days,leads,impaired,movement,gait.,observed,concentration,increased,(by,30,%),220,"%),",dopamine,(24,DOPAC,(35,reduced,"striatum,",(190,(220,with,simultaneously,norepinephrine,(30,Observation,cytokine,both,assayed,cytokines,(IL-1β,TNF-α),There,3-fold,increase,IBA-1,"mRNA,",2-fold,NFκB,dramatic,IkB,striatum.,Taken,"together,",high,dose,induces,neuroinﬂammation,neurotransmission,"disturbance,",specific,each,studied,brain,"region.
",Shortly,after,syphilis,appeared,Europe,time,Columbus’,voyage,New,"World,",big,"pox,",as,it,often,"known,",became,serious,issue,Russia,"diagnosis,","treatment,",prevention.,Members,Russian,royal,family,made,aware,disease,adolescence,onward.,Czar,Peter,Great,had,many,sexual,contacts,could,have,contracted,any,number,sexually,transmitted,diseases,(STDs),quite,common,his,era.,"Nevertheless,",contributions,analyzed,available,sources,contemporary,"doctors,",later,medical,"analyses,",reveal,no,evidence,he,or,other,STD.,Most,"likely,",died,acute,renal,failure,due,urinary,tract,"obstruction.
",Upper,respiratory,world's,most,disease.,etiologic,agents,behind,upper,(URTIs),"are,","fact,",diverse,set,pathogens,such,"influenza,","parainfluenza,","adenovirus,","rhinovirus,",others.,More,than,200,known,be,involved.,Differential,diagnosis,viral,sometimes,complicated,their,diversity,similarity,clinical,presentation.,This,work,devoted,development,method,enables,simultaneous,detection,six,URTI,pathogens:,IAV;,IBV;,RSV;,hAdV;,hPIV2;,hPIV3.,Antibody,microarray,technology,utilized,accomplish,analysis.,preparation,protein,microchip,"creation,","produced,","characterized,",selected,approximately,50,monoclonal,antibodies;,aforementioned,"pathogens,",optimal,antibody,pair,selected.,A,"created,",its,core,working,conditions,optimized.,With,balance,between,convenience,maximal,assay,sensitivity,"mind,",one-step,approach,developed,accomplishing,ELISA-like,“sandwich”,interaction,manufactured,(antibody,microarray).,Reference,strains,used,establish,lower,limits,(LoD),For,"IAV,",LoD,0.25 ng/ml,total,protein.,"viruses,",ranged,1,2 ng/ml,These,slightly,better,those,standard,"ELISA,",inferior,PCR.,"Overall,",believe,good,alternative,existing,"methods,",allowing,relatively,quick,"(overnight),","inexpensive,",screening,several,pathogens.,design,conducive,further,"development,",panel,expanded,include,"members.
",fullerene,"members,","C60,",has,potential,application,various,fields,biomedicine,including,reactive,oxygen,species,(ROS),scavenging,"activity,",inhibiting,tumours,inactivating,viruses,"bacteria,",elaboration,diagnostic,targeted,drug,delivery,tools.,"However,",hydrophobicity,molecule,impedes,practical,"use,",therefore,actuality,research,functionalisation,fullerenes,leading,amphiphilic,derivatives,remains,important.,"work,",water-soluble,carboxylated,derivative,C60[C(COOH)2]3,studied.,Extensive,biomedical,investigation,"compound,","namely,",binding,human,serum,albumin,"(HSA),",radical,diphenylpicrylhydrazyl,(DPPH),"radical,",photodynamic,"properties,",cytotoxicity,embryonic,kidney,(HEK293),cell,"line,",erythrocytes',"haemolysis,",platelet,"aggregation,",genotoxicity,peripheral,mononuclear,cells,(PBMC),conducted.,"Moreover,",dynamic,structural,characteristics,C60[C(COOH)2]3–H2O,binary,obtained,molecular,(MD),"method,",size,distribution,associates,"measured.
","Aims
",our,single-center,retrospective,evaluated,whether,level,different,checkpoint,molecules,bone,marrow,biopsies,course,patients,myelodysplastic,syndrome,"(MDS).
",Methods,"results
",consecutive,cohort,55,MDS,treated,center,2003,2018,technique,able,detect,following,antigens:,"PD-1,","PD-L1,","PD-L2,","LAG-3,","Gal-9,","TIM-3,",CD80.,association,3-year,overall,relapse-free,survival,time-to-progression,analyzed.,Intensive,TIM-3,100%,cases.,"Also,","cases,",moderate,Gal-9,observed.,follow-up,progression,seen,72.9%,CD80,52.1%,low,(p=0.04).,CTLA4,ligands,co-expressed,majority,patients.,General,ligand,associated,incidence,progression:,67.2%,"progressed,",while,group,only,33.3%,cases,(p=0.059).,"CD80,","TIM3,",blasts,risk,according,IPSS,IPSS-R,"scales.
","Conclusions
",preliminary,underlined,heterogeneous,immune,warrants,studies,define,heterogeneity,develop,treatment,"approaches.
","Background
",COVID-19,pandemic,broadly,disrupted,non-invasive,stimulation,(NIBS).,rapid,onset,societal,disruption,evolving,regulatory,restrictions,allowed,systematic,planning,how,continue,throughout,restarted,abated.,urgency,provide,NIBS,intervention,neurological,mental,health,"indications,",catalyst,fundamental,"research,",dampened,parallel,efforts,address,life-threatening,aspects,COVID-19;,rather,need,heightened,mitigate,consequences,related,"COVID-19.
","Objective
",To,facilitate,re-establishment,access,services,operations,current,future,"outbreaks,",discuss,framework,balancing,importance,safety,"considerations,",addressing,needs,all,stakeholders.,focus,Transcranial,Magnetic,Stimulation,(TMS),intensity,transcranial,Electrical,(tES),-,Direct,Current,(tDCS),Alternating,"(tACS).
","Methods
",consensus,paper,provides,guidelines,practices,managing,reopening,clinics,laboratories,through,immediate,ongoing,stages,COVID-19.,document,reflects,experts,domain-relevant,expertise,spanning,"technology,","services,",basic,–,international,perspective.,outline,"aspects,","resources,","optimization,",accommodations,"demographics.
","Results
",model,based,three,phases,(early,"impact,","practices,",preparation),11-step,checklist,(spanning,removing,streamlining,in-person,"protocols,",incorporating,"telemedicine,",COVID-19-associated,adverse,events),proposed.,Recommendations,implementing,social,distancing,sterilization,"equipment,",considerations,positive,populations,"comorbidities,",regarding,resource,era,outlined.,specifically,(sub-)populations,"pediatric,","stroke,","addiction,",elderly.,Numerous,case-examples,across,world,"described.
","Conclusion
","evident,","urgent,",maintain,"pandemic,",anticipating,waves,mind.,proposed,robust,structured,strategy,aims,anticipated,challenges,maintaining,scientific,rigor,"risk.
",Background:,Data,genetic,markers,determine,prognosis,multiple,sclerosis,(MS),still,limited.,galanin,polymorphism,rs948854,MS,been,demonstrated,earlier.,Objectives:,confirm,earlier,findings,distinct,previously,"patients,",characterized,one,candidates,stratification,MS.,Methods:,assess,rate,"progression,",severity,score,(MSSS),Age,Related,Multiple,Sclerosis,Severity,(ARMSS),"used,",along,Progression,Index,(PI).,Results:,minor,allele,"revealed,",confirming,findings.,An,proportion,MSSS > 5,(high,progression),among,G,carriers,(genotypes,AG,GG),compared,AA,genotype.,"Furthermore,",age,correlated,MSSS,value,late,(>30,years).,Conclusion:,"Collectively,",support,contribution,"MS.
","Summary
","Purpose
",describe,analyze,patient,recurrent,idiopathic,exudative,polymorphous,vitelliform,maculopathy,"(AEPVM),",followed,"detail,",propose,"algorithm.
","Design
",Retrospective,observational,"analysis.
","Patient
",adult,male,diagnosed,AEPVM,who,two,relapses,12-month,eight,years,initial,"onset.
",Review,"charts,",multimodal,"imaging,",electrophysiology,repeatedly,underwent,complete,ophthalmic,"examinations,",best-corrected,visual,acuity,testing,"(BCVA),",slit-lamp,fundus,examinations;,digital,"photography,",time-domain,optical,coherence,tomography,(OCT),2009,(Stratus,"OCT,",Carl,Zeiss,"Meditec,",USA),spectral-domain,OCT,2017–2018,"(Spectralis-OCT,",Heidelberg,"Engineering,","Germany),",together,autofluorescence,"(FAF),",fluorescein,angiography,"(FA),",indocyanine,green,"(ICGA),",HRA2,(Heidelberg,Germany);,microperimetry,(MP-1,"microperimeter,","Nidek,",Japan).,Laser,flare,photometry,(Kowa,"FM-600,",Japan),"performed.
",Main,outcome,"measures
",Clinical,features,"AEPVM,",algorithm,rare,"cases.
",Case,report,25-year-old,Caucasian,typical,serous,neuroepithelial,detachment,irregular,retinal,"elevations,",ophthalmoscopically,resembling,"folds,",subsequent,subretinal,accumulation,characteristic,yellow–white,deposits.,Features,case,rarely,"described,",even,yet,"reported,",indocyanine-,fluorescein-negative,intraretinal,cystic,"changes,",optic,disc,hyperfluorescence,"FA,",elevations,choroidal,"thickness,",lack,"recovery,",very,slow,anatomical,improvement,relapses.,Bimonthly,evaluation,SD-OCT,informative,demonstrating,evolution,pathological,"signs.
",chronic,condition,uncertain,outcomes.,variable,presentations,depending,stage,manifestations,imaging,pathologic,process,overlap.,Patients,should,occurs,"slowly,",if,all.,recommended,"ABSTRACT
",Allogeneic,hematopoietic,transplantation,(HCT),high-risk,T,lymphoblastic,leukemia,(T-ALL).,without,HLA-identical,"donor,",haploidentical,(haplo-),HCT,becoming,source,stem,donation.,scarce,predictive,factors,setting.,identified,122,adults,(20%,female;,median,"age,",31,years;,"range,",18,68,years),T-ALL,haplo-HCT,post-transplantation,cyclophosphamide,(ptCy),2010,2017.,duration,living,23,months.,2-year,incidences,relapse,nonrelapse,mortality,45%,"21%,",respectively.,leukemia-free,"(LFS),","(OS),",graft-versus-host,(GRFS),"34%,","42%,","27%,",LFS,OS,highly,influenced,status,"transplantation,",being,49%,"55%,","respectively,",first,remission,(CR1);,34%,"50%,",second,CR,(CR2);,8%,"12%,",active,On,multivariate,"analysis,",OS.,Transplantation,CR2,negatively,affected,"LFS,",whereas,"conclusion,",ptCy,produced,encouraging,results,challenging,particularly,when,performed,CR.,Despite,limitation,small,sample,"size,",type,"conditioning,",calling,into,question,body,irradiation-based,myeloablative,conditioning,"setting.
","HIV,",heavy,"drinking,",smoking,pro-inflammatory,coronary,heart,(CHD).,Interventions,reduce,alcohol,"smoking,",HIV-positive,people,"inflammation,",CHD,risk.,Varenicline,cytisine,proven,therapies,cessation,consumption.,comparative,efficacy,varenicline,consumption,"tested,",nor,effectiveness,reported,"smoking.
",describes,protocol,Studying,Partial,agonists,Ethanol,Tobacco,Elimination,Russians,HIV,(St,PETER,"HIV),",four-arm,parallel-group,randomized,controlled,trial,comparing,"varenicline,","cytisine,",nicotine,replacement,therapy,"(NRT).
",recruiting,four,hundred,drinking,smokers,interested,cutting,down,and/or,tobacco,St.,"Petersburg,",Russia.,Participants,randomly,assigned,receive,either,varenicline + NRT,"placebo,",placebo + active,"NRT,",cytisine + NRT,NRT.,All,participants,evidence-based,counseling,"medication,",placebo.,Outcomes,are:,1),%,past,month,(primary,months),craving;,2),cigarettes,per,3,7-day,point,prevalence,abstinence,and;,3),"risk,",St,addresses,paucity,guide,"smokers.
",Here,evaluate,mast,infection,influenza,A/H5N1,virus,immunized,mice.,CBA,mice,intramuscularly,formalin-inactivated,A/Vietnam/1194/2004,(H5N1)NIBRG-14,(H5N1).,Serum,samples,"7,","12,","14,",21,immunization.,At,infected,intranasally,A/Indonesia/5/2005,(H5N1)IDCDC-RG2,(H5N1),half,animals,receiving,mixture,antihistamines.,67%,vaccinated,protected,lethality,43%,PBS-immunized,group.,Administration,antihistamines,up,85%–95%.,Immunohistochemical,examination,CD117,staining,lungs,larger,quantity,activated,mock-immunized,histamine,blood.,experimental,involvement,they,produce,incomplete,formation,response,vaccination,mismatch,vaccine,"viruses.
",Gestational,methylazoxymethanol,acetate,(MAM),produces,offspring,phenotype,relevant,"schizophrenia,",positive-,negative-like,"symptoms,","deficits,",dopaminergic,"dysfunction,",abnormalities.,show,prenatally,MAM,gestational,17,display,D3,(D3),prefrontal,cortex,"(PFC),",nucleus,"accumbens,",D2,(D2),exclusively,PFC.,change,blood,perfusion,circle,Willis,"hippocampus,",paralleled,enlargement,lateral,"ventricles,",detected,magnetic,resonance,(MRI),techniques.,Peripubertal,non-euphoric,phytocannabinoid,cannabidiol,(30 mg/kg),postnatal,(PND),19,PND,39,reverse,exposed,rats:,i),up-regulation,(only,partially,prevented,haloperidol,0.6 mg/kg/day);,ii),regional,flow,Molecular,modelling,predicted,bind,preferentially,"receptor,",where,act,partial,agonist,conformation,"ionic-lock,",conserved,GPCRs.,"summary,",demonstrate,altered,model;,however,transcript,likely,suggesting,might,contribute,schizophrenia,symptoms,represent,unexplored,target,antipsychotic,"cannabidiol.
",timing,immunosuppressive,combination,(PTCY),transplant,(haplo-HSCT),standardized.,schedules,immunosuppression,haplo-HSCT,509,PTCY,+3,+4,tacrolimus,(group,1;,"n = 215),",cyclosporine,(CSA),mycophenolate,mofetil,(MMF),+5,2;,"n = 170),",CSA + MMF,0,3;,n = 124).,Compared,2,"groups,",younger,(median,46,P = .02),more,received,(77%;,P,<,.01),regimen,containing,"thiotepa,","fludarabine,",busulfan,(84%;,P<,.01).,"years,",44%,"1,",48%,"2,",59%,(P=,.15);,(LFS),"43%,","46%,",53%,.05);,refined,"disease-free,",(rGRFS),"33%,","39%,",36%,(P = .02).,grade,II-IV,GVHD,25%,39%,18%,(P<,.01);,"25%,",24%,.50);,"36%,","37%,",26%,.02);,"26%,","20%,",21%,.35).,start,+1,(hazard,ratio,"[HR],",.58;,P=,.02),improved,rGRFS,"(HR,",.62;,P = .02).,outcomes,PTCY.,administered,improves,"rGRFS.
",Immune,pivotal,synucleinopathy,Parkinson’s,(PD),mediated,neurotoxic,alpha-synuclein.,limited,another,dementia,Lewy,bodies,(DLB).,Recent,impairment.,aimed,estimate,plasma,profile,synucleinopathies,(PD,"(PDD),",DLB).,Plasma,(interferon-gamma,"(IFN-gamma),",interleukin,(IL)-4,"(IL-4),","IL-6,","IL-10,",tumor,necrosis,factor,alpha,"(TNF-alpha),",monocyte,chemoattractant,protein-1,(MCP-1)).,estimated,16,"DLB,","PDD,",28,PD,individuals,disorders,(controls),Luminex,array,system.,Cognitive,assessed,Mini–Mental,State,Examination,(MMSE).,TNF-alpha,IL-6,elevated,"(DLB,",PDD),controls,IL-10,PDD,(p < 0.05).,IFN-gamma,"(p < 0.001,","p = 0.026,",respectively),DLB,(p = 0.032).,"PD,",MCP-1,(p < 0.001).,same,"time,",differences,"TNF-alpha,",found.,pronounced,"demetia.
",Many,metastatic,non-small-cell,lung,cancer,(mNSCLC),experience,first-,second-line,treatment;,options,required,"ARCTIC,",phase,"III,","randomized,",open-label,durvalumab,±,tremelimumab,versus,care,(SoC),≥,third-line,"mNSCLC.
","methods
",ARCTIC,comprised,independent,sub-studies.,Study,A:,126,≥25%,(TCs),expressing,programmed,ligand-1,(PD-L1),(1,:,[up,12,months,10 mg/kg,every,weeks,(q2w)],SoC.,B:,469,PD-L1,TC,<25%,(3 :,durvalumab +,(12,20,mg/kg +,mg/kg,q4w,then,34,10,"q2w),","SoC,",(up,24,q12w).,Primary,end,points:,(OS),progression-free,(PFS),SoC,(study,A;,descriptive,only),"B).
",11.7,(durvalumab),6.8,{hazard,(HR),0.63,[95%,confidence,interval,"(CI),",0.42–0.93]};,PFS,3.8,2.2,[HR,0.71,(95%,"CI,",0.49–1.04)].,11.5,(durvalumab +,tremelimumab),8.7,0.80,0.61–1.05);,P =,0.109].,Median,3.5,groups,0.77,0.59–1.01);,0.056].,Treatment-related,3/4,events:,9.7%,44.4%,(SoC;,A),22.0%,36.4%,heavily,pretreated,"mNSCLC,",clinically,meaningful,improvements,(patients,≥25%);,numerical,<25%).,Safety,profiles,consistent,previous,"studies.
",Trial,"registration
",Clinicaltrials.gov,identifier:,"NCT02352948.
","Objectives
",Because,reference,intervals,(RIs),biochemistry,analytes,matched,population,"defined,",joined,global,values,(RVs),coordinated,IFCC,Committee,Intervals,Decision,Limits,"(C-RIDL).
",According,C-RIDL,harmonized,"protocol,",793,healthy,volunteers,recruited,"Saint-Petersburg,","Moscow,",Yekaterinburg.,tested,analytes.,Sources,variation,RVs,explored,regression,partitioning,sex,judged,deviation,ANOVA.,Latent,abnormal,exclusion,(LAVE),applied,influence,metabolic,inappropriate,sampling,conditions.,RIs,computed,parametric,"method.
",No,appreciable,between-city,Partition,Age-related,"analytes,",especially,females.,trend,exaggerated,nutritional,closely,mass,index,"(BMI),",because,BMI,increases,prominently,age.,"Therefore,",BMI > 28 kg/m2,excluded,determining,age-specific,RIs.,LAVE,effective,lowering,"markers.
",established,biochemical,up-to-date,methods,detailed,consideration,RVs.,similar,participating,"countries.
",Adequate,transplacental,passage,maternal,thyroid,hormone,important,normal,fetal,growth,development.,Maternal,overt,hypothyroidism,hyperthyroidism,"birthweight,",knowledge,gaps,remain,subclinical,function,abnormalities,birthweight—both,general,third,trimester,pregnancy.,examine,associations,"birthweight.
",review,individual-participant,"meta-analysis,",searched,MEDLINE,"(Ovid),","Embase,",Web,"Science,",Cochrane,Central,Register,Controlled,"Trials,",Google,Scholar,inception,Oct,"15,","2019,",prospective,pregnancy,issued,invitations,identify,authors,join,Consortium,Thyroid,Pregnancy.,"pregnancies,",in-vitro,"fertilisation,",pre-existing,medication,"usage,","miscarriages,",stillbirths.,main,(SGA),"neonates,",large,newborn,birthweight.,analysed,mixed-effects,models,adjusting,"BMI,","ethnicity,","parity,","sampling,","sex,",birth.,pre-registered,International,Prospective,Systematic,"Reviews,","CRD42016043496.
","Findings
",2526,published,"reports,",36,cohorts,met,inclusion,criteria.,15,agreed,"participate,",five,unpublished,datasets,"added,",giving,48 145,mother–child,pairs,"exclusions,",whom,1275,(3·1%),(increased,stimulating,[TSH],free,thyroxine,[FT4]),929,(2·2%),isolated,hypothyroxinaemia,(decreased,FT4,TSH).,higher,SGA,euthyroidism,(11·8%,vs,10·0%;,adjusted,difference,"2·43%,",95%,CI,0·43,4·81;,odds,[OR],"1·24,",1·04,1·48;,p=0·015),mean,birthweight,(mean,−38,"g,",−61,−15;,"p=0·0015),",measurement,second.,Isolated,(7·3%,"10·0%,","−2·91,",−4·49,−0·88;,OR,"0·70,",0·55,0·91;,p=0·0073),45,73;,p=0·0012).,Each,SD,TSH,6,g,(–10,−2;,"p=0·0030),",estimates,women,peroxidase,negative,(pinteraction=0·10).,(–25,−17;,"p<0·0001),","second.
","Interpretation
","inverse,",dose-response,(even,within,range),advance,understanding,complex,relationships,"outcomes,",prompt,careful,risks,benefits,levothyroxine,"pregnancy.
","Funding
",Netherlands,Organization,Scientific,Research,(grant,"401.16.020).
",Lorlatinib,third-generation,tyrosine-kinases,inhibitor,(TKI),targeting,ALK/ROS1,fusions.,FDA,approved,lorlatinib,TKI-pretreated,ALK(+),"NSCLC,",approval,ROS1(+),pending.,largest,real-world,NSCLC,harboring,rearrangements,"lorlatinib.
",123,enrolled,retrospectively,(data,cut-off,1/1/2019).,program,therapy.,Outcome,defined,investigator,upon,RECIST,1.1,"criteria.
",106,8,countries.,included,"males,",73,never-smokers,metastases.,Extracranial,(EC),intracranial,(IC),rates,(RR),60,62,"%,",control,(DCR),91,88,Mean,(DoT),23.9 ± 1.6,(mOS),89.1 ± 19.6,ROS1,53,65,EC,IC,RR,67,DCR,92,78,DoT,18.1 ± 2.5,mOS,90.3 ± 24.4,significantly,line,parameters.,events,edema,(48,hyperlipidemia,(47,weight,gain,(25,fatigue,%).,CNS,1–2,"patients.
",shows,outstanding,EC/IC,ALK/ROS1(+),NSCLC.,89 ± 19,supports,90 ± 24,unprecedented,"NSCLC.
",Diabetes,mellitus,dysregulation,complications.,50%,diabetes,suffer,diabetic,"polyneuropathy,",involves,presence,nerve,dysfunction,symptoms.,new,synthetic,arginine-rich,exendin-4,(Peptide,D),complications,caused,"diabetes,","neuropathy,",induced,administering,streptozotocin,(STZ).,Three,Peptide,D,"(0.1,",10 μg/kg).,Byetta®,(1 μg/kg),80,days.,Neuropathic,pain,tactile,allodynia.,STZ-treated,showed,allodynia,unlike,naïve,animals.,histological,diameter,sciatic,fibers,smaller,IHC,myelin,(MBP),Byetta®.,resulted,MBP,myelinated,fibers.,poly-arginine,peptides,promising,"polyneuropathies.
",pattern,auditory,preterm,children,"birth.
","design
",longitudinal,"study.
",involved,271,aged,old.,Children,divided,groups:,70,birth,32–36,(Group,201,22–31,2).,Hearing,"ABR,","ASSR,","OAE,",behavioral,"audiometry,",pure,tone,audiometry.,"Additionally,",some,"children,","CT,","MRI,",GBJ2,evaluations,performed.,Assessments,hearing,3–4,times,year,under,age;,2–3,5,over,Infants,problems,examined,"life,",annual,examinations,"aged.
",SNHL,ANSD,(25.7%),64,(31.8%),Group,occurrence,assessment,(p > 0.05).,Further,children:,child,1.,Four,kinds,noted:,recovery,ANSD;,loss;,transformation,"SNHL,",vice,versa.,"factors,",discussed,"article.
",prematurely,born,tends,"unstable,","infants,",deteriorate,improve.,before,weeks’,gestation,require,least,until,Caution,advised,cochlear,implantation,32,"age.
","Introduction
","II,",single-arm,ASCEND-3,ceritinib,anaplastic,lymphoma,kinase,(ALK),(ALKi)–naive,ALK-rearranged,lines,chemotherapy.,"Here,",final,"results.
",Eligible,(including,asymptomatic,neurologically,stable,metastases),oral,(750,"mg/day,",fasted).,primary,investigator-assessed,(ORR).,Secondary,points,Blinded,Independent,Committee–assessed,ORR;,investigator-,"rate,","response,",(PFS);,(OS);,safety.,Exploratory,patient-reported,"outcomes.
",Of,124,"enrolled,",(98.4%),antineoplastic,medications,(31,[25.0%],"regimens),",49,(39.5%),baseline,cutoff:,January,"22,",2018),52.1,"(range,",48.4–60.1),ORR,67.7%,[CI]:,"58.8–75.9),",16.6,CI:,11.0–23.2).,51.3,42.7–55.3).,(all,"grades,",≥60%,all-causality),diarrhea,"(85.5%),",nausea,"(78.2%),",vomiting,(71.8%).,(14.5%),event,discontinuation.,Health-related,quality,maintained,"treatment.
",Ceritinib,prolonged,"OS,","PFS,",chemotherapy-pretreated,(at,"lines),",ALKi-naive,ALK+,possibilities,angioprotection,osteonecrosis,given,bisphosphonates.,"experiment,",27,injected,saline;,zoledronic,acid,weeks;,"weeks,",added,doses,sulodexide,weeks.,After,constructed,teeth,extracted.,velocity,linear,periodontal,area,extracted,tooth,laser,high-frequency,Doppler,ultrasound,(with,vasoactive,substance,acetylcholine,3%,1min).,structure,bony,tissues,head,"tomography,",saline,microcirculation,use,acid.,mucous,membranes,"and,",greater,"extent,",tissue.,Zoledronic,causes,periosteal,"disorders,",includes,cellular,component,(impaired,endothelium-dependent,vasodilation,membrane,vessels),reducing,tissues.,"Sulodexide,","however,",restoration,reduces,"osteonecrosis.
",subcortical,pathways,motor,spinal,cord,injury,(SCI),animal,models.,descending,interlimb,lumbosacral,excitability,SCI,"humans.
",Ulnar,transcutaneous,electrical,condition-test,paradigm,connections,linking,cervical,segments,non-injured,(n=15),injured,(n=18),"participants.
",Potentiation,spinally,evoked,responses,(sEMRs),ulnar,7/7,volitional,leg,muscle,"activation,",6/11,activation.,"six,",sEMRs,rostral,innervation,entry,"zones.
",Descending,modulation,pools,via,projections,exist,despite,absence,"activation.
","Significance
",Evaluation,"sub-clinical,",spared,residual,"function,",plasticity,"rehabilitation..
",Macrophages,participate,regulation,morphogenetic,placenta.,roles,unclear,placental,macrophages,(Hofbauer,cells).,characterize,steps,production,(intracellular,synthesis,secretion),compare,secretory,villous,"tissue.
",tissue,placentas,pregnancies,9–12,38–40,gestation.,Intracellular,determined,cytometry,antibodies.,Secreted,quantified,cytometric,bead,"ELISA.
",Two,patterns,macrophages.,Cytokines,"(IL-1,","IL-8,",TNFα),basal,stimulated,endotoxin.,"(IL-11,","IL-17A,","IL-17F,","TGF-β,",VEGF),constitutive,did,respond,stimulation.,age-dependent,observed:,secretion,TNFα,IL-8,IL-11,IL-17,third-trimester,first-trimester,cells.,Comparison,suggested,intraplacental,extraplacental,"production.
","Discussion
",would,safe,assume,"production,",correspond,macrophages:,“immune”,“morphogenetic”.,attenuated,supposedly,local,"levels,",confined,Mutations,glucocerebrosidase,(GBA),cause,Gaucher,"(GD),",lysosomal,storage,disorder,"(LSD),",Parkinson's,(PD).,Lysosome,functionality,plays,extracellular,vesicles,(EVs),content.,EVs,GD,terms,"amounts,","distribution,",cargo.,sequential,centrifugation,сryo-electron,microscopy,"(cryo-EM),",nanoparticle,tracking,"(NTA),",light,scattering,(DLS).,exosomal,HSP70,tetrasponins,cytometry.,Protein,profiling,mass-spectrometry,(shotgun,analysis).,morphology,exosomes,derived,cryo-EM,DLS,"(р<0.0001,","p < 0.001,",confirmed,mode,NTA,(p < 0.02).,Cryo-EM,double,multilayer,enriched,surface,"(CD9,","СD63,",CD81),exosome-associated,Proteomic,proteins,pathogenesis.,"Thus,",striking,alteration,"morphology.
",perform,postural,neuropsychiatric,tremor,"(ET),","phenotypes,",combined,ET,"(ET-PD).
",169,(1.0–2.0),111,advanced,(2.5–3.0),Hoehn,Yahr,"scale,",26,ET-PD,study.,Motor,non-motor,standardized,scales,"stabilometry.
",ETPD,milder,parkinsonism,posture,walking,scales.,"ETPD,",PD.,Using,"stabilometry,",discovered,indexes,stabilometric,parameters,although,"ET.
",conducted,helpful,differential,diagnosis.,helps,expand,"ET-PD.
",recent,highlighted,autophagy,pathway,(ALP),Genes,GBA,"LRRK2,",harbor,mutations,ALP.,"α-synuclein,",encoded,SNCA,"gene,",degraded,mainly,"ALP,",mutations/multiplications,chaperone,ALP,functions.,PD-related,"genes,","PRKN,","PINK1,","TMEM175,","SMPD1,","CTSD,",CTSB,"more,",Understanding,relationship,crucial,uncovering,long-awaited,neuroprotective,therapies.,"review,",will,"(other,",atypical,forms,"Parkinsonism,",review).,genes,"proteins,","PD.
",elucidate,dynamical,complexity,impulse,sensory,neurons,emergence,antinociceptive,painful,stimulus.,solve,problem,bifurcation,enabled,us,relations,nociceptive,neuron,effect.,shown,mechanism,suppression,ectopic,bursting,discharges,base,neurons.,Under,potassium,"blocking,",connected,entirely,modification,activation,gating,NaV1.8,sodium,channels,action,comenic,non-opioid,analgesic,anoceptin.,explain,neuropathic,"pain.
",Metoclopramide,widely,abortive,migraine,advantage,having,"antiemetic,",properties.,metoclopramide,"migraine,",anti-cephalalgic,elucidated.,Taking,account,key,trigeminovascular,"pathophysiology,",investigate,neurogenic,dural,valid,electrophysiological,neurovascular,nociception.,Extracellular,recordings,second-order,dura-sensitive,trigeminocervical,(TCC),anaesthetised,Cumulative,infusion,(three,30 min,"intervals,",5 mg/kg,i.v.,"step,",n = 8),dose-dependently,suppressed,firing,TCC,"stimulation,",maximally,30%[0–49%],(median[Q1-Q3]),4%[0–30%],"level,",respectively,(both,"p = 0.001,",(n = 8)).,By,"contrast,",separate,cumulative,(5 mg/kg,n = 6),vehicle,(n = 6),p > 0.05).,unable,does,suppress,anti-migraine,action.,here,neurophysiological,therapeutic,"migraine.
",Exposure,lipopolysaccharidein,affects,disturbances,potentiation,functions,"rats,
",Intranasal,disrupts,metabolism,"hippocampus,
","diseases,
",immunoassay,"pathogens,
",Biological,dynamics,simulation,"C60[C(COOH)2]3,
",checkpoints,predictor,"syndrome,
",Guidelines,TMS/tES,"pandemic,
",sclerosis:,"onset,
",Eight-year,"maculopathy,
",Haploidentical,Post-Transplantation,Cyclophosphamide,Cell,Acute,Lymphoblastic,Leukemia:,Report,European,Society,Blood,Marrow,Leukemia,Working,"Party,
",Design,drinkers,daily,"Russia,
",Mast,degranulation,release,influenza-sensitized,"mice,
",Altered,reversed,peripubertal,"treatment,
",Timing,Transplantation:,Comparative,Behalf,Party,"Transplantation,
",synucleinophaties,"dementia,
",ARCTIC:,"cancer☆,
",Establishing,major,population:,part,"values,
",Association,birthweight:,"meta-analysis,
",GLASS:,Global,Study:,real,"patients,
",Therapeutic,exenatide,neuropathy,Changes,premature,"study,
",Final,Overall,Survival,Other,Efficacy,Results,From,ASCEND-3:,Phase,II,of Ceritinib,ALKi-Naive,ALK-Rearranged,"NSCLC,
",Disorders,bisphosphonate,osteonecrosis:,Interlimb,"injury,
","macrophages,
","disease,
",Postural,instability,disturbance,overlapping,"Disease,
",Autophagy,disease;,"genetics,
",Mechanisms,"emergence,
",Influence,Trigeminovascular,Nociception:,Possible,Anti-migraine,Mechanism,"Action,
"
